乌瑞芦单抗 - Names and Identifiers
乌瑞芦单抗 - Introduction
Urelumab is an immune antibody used to treat certain types of cancer, particularly breast and colorectal cancer. It is a monoclonal antibody that blocks the undesirable proliferation and spread of cancer cells by binding to proteins on the surface of specific cancer cells.
Urelumab is prepared by biotechnology. First, a specific antigen is injected into the animal to provoke an immune response. After that, the lymphocytes that can efficiently bind the antigen are selected and fused to the special lymphoblastoma cells to form the hybridoma. Finally, cells containing the specific antibody are collected from the hybridoma, cultured and purified to obtain Urelumab.
The dosage and duration of use of Urelumab should be according to the doctor's prescription. During use, there may be some side effects, such as pain, nausea, vomiting, diarrhea, rash, etc. In addition, Urelumab may also cause immune-related adverse reactions, such as allergic reactions, inflammatory reactions, and immunosuppression.
However, Urelumab has important clinical value in the treatment of cancer and is widely used in clinical practice. Before or during use, patients should discuss in detail with their doctor and understand the possible risks and benefits in order to make an informed treatment decision.
Last Update：2024-04-09 21:01:54